Literature DB >> 23968303

Antioxidant treatment and outcome of Cortinarius orellanus poisoning: a case series.

Scott-Oliver Grebe1, Martin Langenbeck, Andreas Schaper, Siegmar Berndt, Duaa Aresmouk, Stefan Herget-Rosenthal.   

Abstract

OBJECTIVES: To study the frequency, severity, and long-term outcome of renal injury in Cortinarius orellanus poisoning, to evaluate the association between the ingested amount of C. orellanus and outcome, and to evaluate the effect of N-acetylcysteine and corticosteroid treatment on outcome.
METHODS: Case series of eight patients. Diagnosis and severity of acute kidney injury (AKI) and chronic kidney disease (CKD) were classified according to current AKI and CKD definitions. N-acetylcysteine and corticosteroids were administered to six patients, former according to the standard for paracetamol poisoning. MAIN
FINDINGS: All patients developed AKI, six in the most severe stage and four required renal replacement therapy (RRT). After 12 months, seven patients presented with CKD, of whom three required chronic RRT and further two were in advanced CKD. AKI and CKD severity highly correlated with the consumed amounts of Cortinarius orellanus (r = 0.98, p < 0.001 and r = 0.78, p = 0.02, respectively) but not with N-acetylcysteine and corticosteroid treatment.
CONCLUSIONS: AKI and CKD by current definitions and classifications are frequent and severe after Cortinarius orellanus poisoning. The ingested amount of Cortinarius orellanus correlates with the severity of both AKI and CKD. N-acetylcysteine and corticosteroid treatment do not seem to have a beneficial effect on either AKI or CKD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23968303     DOI: 10.3109/0886022X.2013.826110

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  3 in total

Review 1.  [Mass poisoning events].

Authors:  H Desel
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-12-18       Impact factor: 0.840

2.  Administration of antioxidants in chronic kidney disease.

Authors:  Mohamad Reza Tamadon; Mehrdad Zahmatkesh; Seyed Seifollah Beladi Mousavi
Journal:  J Nephropharmacol       Date:  2015-01-01

Review 3.  Bardoxolone methyl: drug development for diabetic kidney disease.

Authors:  Hironori Kanda; Kengo Yamawaki
Journal:  Clin Exp Nephrol       Date:  2020-06-27       Impact factor: 2.801

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.